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Neutropenia is the main dose-limiting toxicity occurring in docetaxel treatment. The objective of this study was to identify
pharmacodynamic (PD) factors responsible for the neutropaenia caused by docetaxel. Data were obtained from 92 patients treated
with docetaxel as a monochemotherapy in two different treatment centres. A semiphysiological population pharmacokinetic–
pharmacodynamic (PK/PD) model was applied to describe the time course of neutrophils and the neutropaenic effect of docetaxel.
The plasma docetaxel concentration was assumed to inhibit the proliferation of neutrophil precursors through a linear model: Drug
effect¼Slope Conc. Slope corresponds to the patients’ sensitivity to the neutropaenic effect of docetaxel. Covariate analysis was
performed by testing the relationship between the patients’ characteristics and Slope using the program NONMEM. The
neutropaenic effect of docetaxel showed a high interindividual variability. Three significant PD covariates were identified: serum
a1-acid glycoprotein levels (AAG), level of chemotherapy pretreatment, and treatment centre. Extensive pretreatment was
associated with an increase in Slope values meaning a higher haematotoxicity. An increase in AAG was associated with a decrease of
both Slope and docetaxel plasma clearance. Patients treated in one centre had both higher Slope and docetaxel clearance. The
centre effect (most likely due to a bias in the PK part of the study between the two centres) reveals the robustness of the PK/PD
model. Individual dosing of docetaxel should be based on previous chemotherapy but not on the AAG level since it has a similar
influence on PD and PK docetaxel parameters. This methodology should be applied to further investigate elderly patients and to
identify more precisely the characteristics of previous chemotherapy that contribute to the cumulative myelotoxicity.
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Neutropenia is the main dose-limiting toxicity of docetaxel
treatment. This toxicity may be life-threatening, and often imposes
a delay on subsequent administration that affects treatment
efficacy. Altered pharmacokinetics was identified as a factor
involved in the toxicity. A relationship has been observed between
systemic exposure to docetaxel, as measured by the AUC, and
neutropenia (Baker et al, 2006). Pharmacokinetic studies per-
formed by Bruno et al (1996) based on a population pharmaco-
kinetic (PK) analysis of data obtained during the clinical
development of docetaxel showed that docetaxel clearance (CL)
was related to hepatic function and body surface area (BSA), thus
justifying measuring BSA and adjusting the dose in patients with
elevated alkaline phosphatase and transaminases levels. The effect
of age on CL was statistically significant but slight: a 6.7% decrease
in mean CL in patients aged from 56 to 71 years. Minami et al
(2004) did not observe any consistent difference in CL between
elderly (X75 years) and non-elderly patients. However, they
concluded that elderly patients were more sensitive to docetaxel
exposure than the younger patients. More generally, evidence of
interindividual variability in docetaxel haematotoxicity can be seen
from all these pharmacokinetic–pharmacodynamic (PK/PD)
studies: patients with similar AUC may have different neutrophil
counts at nadir.
The current study describes population PK/PD analyses based
on data from 92 patients included in two studies of single-agent
docetaxel treatment. The analyses utilise a semimechanistic model
(Figure 1) proposed by Friberg et al (2002), describing the effect of
cytotoxic drugs on bone marrow production. After the drug
administration, at any time, the cytotoxic effect of the drug (Edrug)
on the proliferating neutrophil cells is proportional to the
plasma drug concentration (Conc) according to the equation:
Edrug¼Slope Conc. Slope corresponds to the patient sensitivity
to the neutropaenic effect of docetaxel. Its value is subject to
interindividual variability. The objective of this PK/PD analysis
was to identify pharmacodynamic factors (PD covariates) involved
in docetaxel neutropenia. That was performed by integrating
patients’ characteristics into the model and evaluating their
contribution to the interindividual variability in Slope values.
The advantage of this model was the consideration of the whole
concentration–time profile rather than a single PK variable such
as AUC.
MATERIALS AND METHODS
Patients, drug treatment, and haematological evaluation
Data were obtained from 92 patients who were included in two
separate clinical trials. The first one was carried out in the Institut
Claudius-Regaud of Toulouse and was designed to correlate
docetaxel CL to dexamethasone clearance to use as a probe of
docetaxel elimination (n¼37) (Puisset et al, 2007). The second
trial (n¼55) was performed in the Ho ˆpital Cochin (Paris) to study
the relationship between docetaxel toxicity and genetic poly-
morphisms (Tran et al, 2006). The two protocols were approved by
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stheir regional ethical committees. All patients provided written
informed consent before enrolment in the study. Patients’
characteristics are summarised in Table 1. In both studies,
docetaxel (Taxotere
s, Aventis Pharma, Paris, France) was
administered intravenously as a monotherapy over 1h, at doses
ranging from 70 to 100mgm
 2. All patients received an
antiallergic and antiemetic premedication. Complete blood cell
counts were performed weekly after the first cycle. No patient
received any prophylactic granulocyte colony-stimulating factor.
PK sampling and assay
Blood samples were collected before infusion, 0.5, 2, and 6h after
the end of infusion for the Toulouse Centre; before infusion, at the
end of infusion, and 6h after the end of infusion for the Paris
Centre. The plasma docetaxel concentrations were measured by
reverse-phase HPLC using UV absorbance detection, according
to previously described methods (Puisset et al, 2004; Tran et al,
2006). The coefficients of variation for interday reproducibility and
precision were lower than 15.7 and 6.0% for the analyses
performed in Toulouse and Paris, respectively.
PK/PD analyses
Data were analysed according to a nonlinear mixed effects
population approach using NONMEM (Beal and Sheiner, 1982)
(version V, level 1.1; GloboMax, Hanover, MD, USA). First, a PK
analysis of docetaxel plasma concentrations vs time was performed
in order to obtain docetaxel PK parameters (POSTHOC values)
and a complete concentration-vs-time profile for each patient.
Secondly, the PK/PD analysis of ANC vs time was performed using
these individual PK parameters.
PK analysis
Individual-specific PK parameters were obtained by analysis of
docetaxel plasma concentrations vs time using the Bayesian
estimation method previously proposed by Baille et al (1997).
Complete plasma docetaxel concentration-vs-time profiles used for
the PK/PD analysis were generated from this analysis. Moreover,
the relationships between the covariates and plasma docetaxel CL
were evaluated. Seven covariates were tested: gender, AGE, BSA,
serum a1-acid glycoprotein level (AAG), treatment centre
(CEN¼0o r¼1 if data corresponded to Paris or Toulouse,
respectively), pretreatment PTT1 (PTT1¼0o r¼1 if patients
underwent their first line of chemotherapy or not, respectively),
and PTT2 (PTT2¼0o r¼1 if patients had less than two lines, or at
least two lines of chemotherapy before docetaxel, respectively).
The FOCE method was implemented for the estimation of the
different parameters.
PK/PD model
The PD model was that proposed by Friberg et al (2002) for
docetaxel (Figure 1). The model mimics the maturation chain of
neutrophils and was based on five compartments: one compart-
ment that represented progenitor cells [Prol], three maturation
compartments [Transit], and a compartment of observed circulat-
ing neutrophils [Circ]. The generation of new cells in [Prol] was
dependent on the number of cells in the compartment, that is,
self-renewal or mitosis. A proliferation rate constant determining
the rate of cell division (kprol), and a feedback mechanism, was
modelled as (Circ0/Circ)
g where Circ was the circulating blood
cell count at a given time and Circ0 the baseline circulating cell
counts before docetaxel administration. As in the original model,
the rate constants were assumed to be equal: kprol, ktr, and kcirc for
the rate of cell division, of the transit between compartments,
and the physiological elimination of circulating cells, respectively.
Three system-related parameters were estimated by NONMEM
analysis: Circ0, MTT as the mean transit time through the
maturation delay chain, and g as the power factor for the feedback
mechanism. Docetaxel concentration in the central compartment
(Conc, corresponding to the plasma concentration) is assumed
to induce cell loss from [Prol]. The drug effect, Edrug, was
Prol Transit
1
Transit
2
Transit
3
Circ
E
drug
Kprol (=ktr)
ktr ktr ktr ktr
MTT
Circ
Circ0 Feedback =

Figure 1 Pharmacokinetic–pharmacodynamic model describing myelo-
suppression following docetaxel administration (modified from Friberg et al,
2002). kprol, rate of cell division; ktr, rate of transit between compartments;
kcirc, rate of physiological elimination of circulating cells; Circ0/Circ, baseline
circulating cell counts before drug administration/circulating blood cell
count at a given time; Prol, compartment representing progenitor cells;
Edrug, cell loss, function proportional to docetaxel concentration in central
compartment; MTT, mean transit time through the maturation delay chain.
Table 1 Patient characteristics: comparison between centres
All patients n¼92 Toulouse n¼37 Paris n¼55
Patients characteristics Mean (range) Mean (range) Mean (range) P-values
Age (years) 60.7 (46–77) 60 (46–77) 61 (47–75) NS
Body weight (kg) 70.8 (39–106) 70.9 (49–106) 70.7 (39–100) NS
Body surface area (m
2)
a 1.77 (1.35–2.20) 1.78 (1.46–2.10) 1.77 (1.35–2.20) NS
a1-Acid glycoprotein (gl
 1) 1.29 (0.46–2.98) 1.51 (0.57–2.98) 1.13 (0.46–2.64) o0.01
Serum albumin (gl
 1) 36 (16–45) 35 (23–43) 37 (16–45) NS
Number Number Number
AST: 41.5ULN/o1.5ULN 12/80 8/29 4/51 o0.01
ALT: 41.5ULN/o1.5ULN 8/84 5/32 2/53 o0.01
Gender (male/female) 47/45 19/18 28/27 NS
Number of lines of previous chemotherapy treatments: 0/1/2 or 42 27/44/21 10/19/8 17/25/13 NS
Performance status: 0/1/2/3 13/61/16/2 8/25/3/1 5/36/13/1 o0.01
Docetaxel doses: 70/75/85/100mgm
 2 1/29/39/23 0/21/0/16 1/8/39/7 o0.001
Primary disease: breast/prostate/lung/others 31/27/15/19 15/12/2/8 16/15/13/11 NS
ALT¼serum alanine amino transferase; AST¼serum aspartate amino transferase; NS¼nonsignificant; ULN¼upper limit of normal.
aCalculated according to the Dubois
formula.
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sproportional to Conc: Edrug¼Slope Conc. The interindividual
variability was estimated for Circ0, MTT, and Slope according
to an exponential model. A log-normal distribution of the
parameters was assumed. A HYBRID method (FOCE method for
Circ0, FO method for MTT and Slope) was applied for the
estimation of parameters. A proportional model for residual
variability was used.
Relationships between covariates and PD parameters
The analysis of the PD covariate effect was limited to the
Slope parameter. Seven covariates were evaluated: gender,
AGE, BSA, AAG, CEN, PTT1, and PTT2. For continuous
covariates, the impact of each covariate on the Slope value was
tested according to the following equation using, for example,
AGE : TVSlope ¼ y1ðAGE=meanAGEÞ
y2where y1 is the typical
value of Slope (TVSlope) for a patient with the mean covariate
value, and y2 is the estimated influential factor for the covariate
AGE. Dichotomous covariates (gender, centre, and pretreatment)
were tested according to the equation using, for example, PTT:
TVSlope¼y1 y2
PTT with PTT¼1o r¼0 for patients pretreated or
not pretreated. Full and reduced models (one parameter less) were
compared by the w
2 test of difference between their respective
objective function values (OBJ). OBJ is equal to minus twice the log
likelihood of the data. For the forward search, each covariate was
univariately introduced into the basic model. A covariate was
considered as significant if it decreased the OBJ by at least 3.84
(Po0.05, 1 degree of freedom). An intermediate model including
all significant covariates was then obtained. Therefore, a stepwise
backward elimination procedure was carried out. Deletion of the
covariate from the intermediate model should be associated with
an increase of the OBJ of at least 10.83 (Po0.001, 1 degree of
freedom) in order to consider this covariate as relevant. Moreover,
95% confidence intervals (95% CIs) corresponding to the
estimated influential factor (y2) were calculated from the standard
errors estimated by NONMEM. At each step of the covariate
analysis, the 0 value should be outside the 95% CI in order to
consider the covariate as significant.
y = 1.04x – 213  
R
2 = 0.912
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Figure 2 Observed neutrophil (ANC) values (A) or individual weighted residual (B) vs individual predicted values (- - - , identity line; —, regression line).
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sRESULTS
PK analysis
There was a good agreement between observed plasma docetaxel
concentrations and those estimated by the Bayesian method
(regression line: y¼1.002xþ0.04, with R
2¼0.99), indicating that
individual docetaxel plasma profiles were adequately generated.
Mean (range) plasma docetaxel clearance and AUC were 40.0
(15.9–74.4)lh
 1 and 4.1 (1.9–8.7)mghl
 1, respectively. An
increase in AAG levels was associated with a decrease in CL, and
patients treated in Toulouse had higher CLs than those treated in
Paris. Multivariate analysis led to the following PK covariate model
(795%):
CLðl=hÞ¼31:3ð 3:1ÞðAAG=1:29Þ
 0:412ð 0:190Þ1:7ð 0:3Þ
CEN
with CEN¼0o r¼1 if data corresponded to Paris or Toulouse,
respectively.
PD model and analysis of covariates
The structural model described well the time course of ANC after
docetaxel administration (Figure 2A and B). Figure 3 shows
predicted and observed neutrophil counts for an individual
selected on the basis of the magnitude of his typical residual
error (average absolute weighted residual is similar to the
population mean value, i.e., 36%). The mean parameters of the
PD model and their corresponding interindividual variability are
shown in Table 2. Values previously obtained for docetaxel by
Friberg et al (2002) are indicated for comparison. Figure 4 shows
all the observed ANC values and population-predicted ANC–time
profile (i.e., PRED vs time corresponding to the mean system-
related parameters and Slope values following the mean docetaxel
dose of 150mg).
Analysis of covariates
During the individual testing, four covariates (i.e., AGE, PTT2,
AAG, and CEN) were significantly correlated with Slope. Figure 5
shows the individual Slope values vs each of these covariates. The
intermediate model was based on these four covariates. The
absolute y value corresponding to AGE was not significantly
different from 0. The final covariate model was based on PTT2,
AAG, and CEN since their corresponding CIs excluded the 0 value,
and deletion of each of them was associated with a significant
increase of the OBJ. The relationship between the Slope values and
the covariates is shown in Table 3. Docetaxel sensitivity (Slope
values) was increased overall by 69% in patients previously treated
by at least two previous chemotherapy regimens (PTT2). The
figure for patients treated at the Toulouse Centre was 82%, and was
nearly inversely proportional to the AAG level. The effect of AAG
and PTT2 on the ANC profile is shown in Figure 6 and shows that
PTT2 had a real impact on the ANC count but AAG did not due to
its simultaneous effect on the PK of docetaxel.
DISCUSSION
The semimechanistic PK/PD model proposed by Friberg et al
(2002) described well the ANC values observed after docetaxel
administrations in our patient population. The typical values
corresponding to the system-based PD parameters (Circ0, MTT,
and g) and those related to the drug effect (Slope) were consistent
with the values previously obtained for docetaxel. Goodness-of-fit
for the PK/PD model is illustrated by the agreement between
the observed values of ANC and the predicted individual values
(Figure 2), and the representative example of the data from a single
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Figure 3 Individual predicted and observed neutrophil time course of a
‘typical’ patient.
Table 2 Mean parameters and IIV corresponding to the structural
pharmacodynamic model
Study
Present study Friberg et al (2002)
parameters Estimate RSE (%) Estimate RSE (%)
Circ0 (10
9l
 1) 4.41 6.3 5.05 1.9
IIV Circ0 (%) 49.2 18.3 42 7
MTT (h) 96.2 8.8 88.7 2.5
IIV MTT (%) 25.5 40.2 16 24
g 0.146 42.5 0.161 3.7
Slope (mg
 1ml) 7.76 7.4 10.6 5.2
IIV Slope (%) 96.5 42 60 14
Proportional residual error (%) 35.6 21.3 27.3 —
Additive residual error
(ANC 10
9l
 1)
Not applicable — 1.15 —
Circ0¼baseline circulating cell counts before drug administration; g¼power factor
for the feedback mechanism; IIV¼interindividual variability; MTT¼mean transit time
through the maturation delay chain; RSE¼relative standard error related to the
corresponding variance term; Slope¼drug sensitivity. Values of the present study and
those previously obtained by Friberg et al (2002) for docetaxel.
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Figure 4 All observed ANC values and population-predicted ANC–
time profile for a patient receiving a mean dose of 150mg (85mgm
 2 for a
patient with a BSA of 1.77m
2).
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spatient (Figure 3). The patient is also representative of a limitation
of the model: the lowest ANC values (below 100 10
6l
 1) were
poorly adjusted to the individual predicted values that were higher
than the observed values. However, these predicted ANC values
were within the 0–500 10
6l
 1 range (corresponding to grade 4
haematological toxicity), which is considered as clinically critical.
The main advantage of this approach was to allow us to integrate
data from patients with sparse ANC values. The normal evaluation
of haematological toxicity (i.e., based on the nadir value) cannot be
carried out when some post-chemotherapy ANC counts are
missing.
An unexpected result was that the patients’ sensitivity was
significantly higher (þ82% in Slope values) in patients treated in
the Toulouse Centre (CEN¼1) than those treated in Paris
(CEN¼0). This PK/PD result should be analysed together with
that of the PK analysis: docetaxel CL was also higher (þ70%) for
CEN¼1. We may hypothesise that differences at the analytical
level (i.e., HPLC procedure) between the two centres were
responsible for a bias in the determination of docetaxel CL. Since
the plasma docetaxel levels seemed to have been underestimated in
Toulouse compared with those determined in Paris, the PK/PD
analysis relating cytotoxic effects (Edrug) to those docetaxel plasma
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Figure 5 Individual predicted Slope values vs age, a1-acid glycoprotein, pretreatment, and treatment centre.
Table 3 Relationship between docetaxel neutropaenic sensitivity (Slope in mg
 1ml) and patients’ covariates
Models Mean (795% CI) IIV Slope (%) DOBJ
a P-values
Intermediate model
Slope ¼ y1ðAGE=60:7Þ
y2ðAAG=1:29Þ
y3 y
PTT2
4 y
CEN
5 y1¼7.91 (71.64) y2¼ 0.68 (71.01)
y3¼ 0.74 (70.18) y4¼1.48 (70.45)
y5¼1.77 (70.49)
44  5N S
Final model
Slope ¼ y1ðAGE=1:29Þ
y2y
PTT2
3 y
CEN
4 y1¼7.40 (71.22) y2¼ 0.72 (70.18)
y3¼1.69 (70.32) y4¼1.82 (70.46)
44 — —
Alternative models
Slope ¼ y1ðAAG=1:29Þ
y2y
CEN
3 y1¼7.73 (71.45) y2¼ 0.80 (70.27)
y3¼1.88 (70.62)
52 +39 o0.001
Slope ¼ y1ðAAG=1:29Þ
y2y
PTT2
3 y1¼7.86 (71.39) y2¼ 0.51 (70.27)
y3¼ 1.94 (70.58)
59 +46 o0.001
Slope ¼ y1y
PTT2
2 y
CEN
3 y1¼7.5 (71.4) y2¼1.42 (70.69)
y3¼2.15 (70.75)
57 +71 o0.001
AAG¼serum a1-acid glycoprotein level; CEN¼0o r ¼1 if data corresponded to Paris or Toulouse, respectively; CI¼confidence interval; IIV¼interindividual variability;
NS¼nonsignificant; PTT2¼0o r¼1 if patient received less than two lines, or at least two lines of chemotherapy before docetaxel, respectively.
aDifference in objective function
value in comparison with final covariate model.
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slevels led to higher Slope values for the Toulouse data. The
difference in blood sampling between the two centres may also be
responsible of an overestimation of the individual docetaxel CL in
Toulouse in comparison with those determined in Paris, generat-
ing this apparent difference in Slope values. Rather than revealing
a clinically pertinent covariate, these results show the robustness
of the PK/PD model: the PK/PD analysis corrects a bias at the
PK level.
Slope was significantly dependent on the patient’s pretreatment.
Patients who received at least two treatments of chemotherapy
before docetaxel had a value almost twice as high as those not
pretreated or who had previously received only one line of
chemotherapy. The term 1.69
PTT2 from the final covariates model
(Table 3) suggests that the dose of docetaxel used as a third
line should be reduced by about 40% from the usual dose to
give the same degree of neutropaenia. This result indicates that
the bone marrow reserve of the patients seems to be affected by
the number of previous chemotherapy treatments. We may
anticipate that the neutropaenic effect of docetaxel is also
dependent on the quality and the extent of the prior chemo-
therapy. A more precise description of the myelotoxic aspects
of the chemotherapy would have improved the model, but
subdivision of the data set to accommodate these additional
descriptions of the prior chemotherapy would require a larger
number of patients.
The baseline AAG level was the other significant covariate.
Increased AAG resulted in a decreased Slope value. This relation-
ship was also expected since docetaxel is extensively bound to
AAG, and this is mainly responsible for interindividual variability
in docetaxel unbound fraction (fu) (Urien et al, 1996). In the
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spresent NONMEM analysis, the Slope values link total plasma
docetaxel concentrations and neutropaenic responses. That is why,
between two patients with equal total plasma docetaxel concentra-
tions, the one with higher fu value due to a lower AAG level, will
have a higher Slope value. By an original and semimechanistic-
based approach, these results confirm those obtained by Baker
et al (2005) by a two-stage approach: the percentage decrements in
ANC were better correlated with the AUC of unbound docetaxel
than with that of total docetaxel. However, the relationship
between the Slope values and the AAG level does not lead to
dosing recommendations based on the AAG level. Indeed, several
studies have confirmed that the docetaxel CL is dependent on fu,
with a lower CL in patients with high AAG levels (Urien et al, 1996;
Baker et al, 2005). Interindividual variability in AAG is not
associated with marked changes in the AUC of free docetaxel. As
illustrated by Figure 6A, the increase in AAG was associated with
only a modest decrease in toxicity since it was also associated with
a decrease in docetaxel CL. All these results suggest that dose
should not be individualised according to baseline AAG level, but
that protein binding phenomena should be considered when the
relationship between total plasma docetaxel concentrations and PD
is evaluated.
As previously mentioned in the introduction, several authors
have suggested that elderly patients experienced more profound
docetaxel myelotoxicity (Minami et al, 2004; ten Tije et al, 2005).
On the contrary, our PK/PD analysis showed that the Slope values
did not increase with age, as the plot of Slope values against age
(Figure 5) did not show any trend. However, it should be noted
that all but two of our patients were younger than 75 years.
In conclusion, this analysis enabled us to identify the
chemotherapy administered before docetaxel treatment as a
significant PD factor in haematotoxicity. These results suggest
that the lower dose of docetaxel for treatment of prostate cancer
(i.e., 75mgm
 2) vs breast cancer (100mgm
 2) remains empirical
since gender was not a factor contributing to a greater sensitivity.
More generally, it illustrated the potential use of PK/PD models to
identify subgroups of patients with a higher risk of toxicity. In
particular, this methodology should be applied to further explore
the haematotoxicity of docetaxel in older patients and to identify
more precisely the characteristics of the previous chemotherapy
that contribute to the cumulative myelotoxicity.
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